v3.25.0.1
ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Narrative) (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
Sep. 01, 2023
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
item
Jun. 30, 2024
USD ($)
item
Mar. 31, 2024
USD ($)
item
Dec. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
item
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]                    
Research and development               $ 163,754 $ 124,010 $ 73,015
Contingent consideration liability $ 139,358             123,235 139,358  
Goodwill $ 1,434,540         $ 197,471   1,432,387 1,434,540 197,471
Acquisition related costs               $ 29,623 $ 68,274 5,959
Customer Relationships & Other Intangibles [Member]                    
Business Acquisition [Line Items]                    
Weighted average amortization period 10 years 7 months 6 days             10 years 7 months 6 days 10 years 7 months 6 days  
Developed Technology [Member]                    
Business Acquisition [Line Items]                    
Weighted average amortization period 8 years             8 years 8 years  
Fibriant B.V. [Member]                    
Business Acquisition [Line Items]                    
Research and development         $ 12,600          
Contingent consideration payment         12,000          
Asset Acquisition, Consideration Transferred         12,000          
Achievement Of Certain Performance Obligation [Member] | Fibriant B.V. [Member]                    
Business Acquisition [Line Items]                    
Additional contingent consideration         $ 10,000          
Harvest Biologics, LLC [Member]                    
Business Acquisition [Line Items]                    
Purchase price, preliminary post-closing adjustments           $ 100       100
Purchase price allocation finalization period           1 year        
Inventory acquired           $ 3,000       3,000
Business combination, consideration transferred           30,000        
Goodwill           14,200       14,200
Harvest Biologics, LLC [Member] | Customer Relationships & Other Intangibles [Member]                    
Business Acquisition [Line Items]                    
Intangible assets acquired           $ 10,500       $ 10,500
Weighted average amortization period           20 years       20 years
Harvest Biologics, LLC [Member] | Developed Technology [Member]                    
Business Acquisition [Line Items]                    
Intangible assets acquired           $ 2,400       $ 2,400
Weighted average amortization period           8 years       8 years
Series of Individually Immaterial Business Acquisitions [Member]                    
Business Acquisition [Line Items]                    
Number of acquisitions | item     1 1 1   1      
Weighted average amortization period         10 years          
Goodwill         $ 17,900          
Payments to Acquire Businesses, Gross     $ 100 $ 100 500          
Business combination, consideration transferred             $ 200      
Contingent consideration liability     $ 4,000 $ 1,900            
Contingent payments, performance period     5 years 5 years     10 years      
Goodwill     $ 4,100 $ 2,000     $ 4,600      
Contingent consideration payment         19,100   $ 4,400      
Fair value adjustments to inventory         $ 1,800          
NuVasive Merger Agreement [Member]                    
Business Acquisition [Line Items]                    
Common stock, par value | $ / shares               $ 0.001    
NuVasive [Member]                    
Business Acquisition [Line Items]                    
Unaudited pro forma net income                 $ 187,585  
Future services amount, not yet expensed   $ 29,400           $ 29,400    
Acquisition related costs recognized               16,900    
Inventory acquired $ 558,034             575,003 558,034  
Payments to Acquire Businesses, Gross               2,603,836 2,603,836  
Business combination, consideration transferred   2,603,836                
Goodwill 1,234,475             $ 1,209,940 $ 1,234,475  
Acquisition related costs $ 111,400 12,900                
Repaid debt outstanding   420,762                
Fair value of assumed equity awards   28,635                
Awards vested post acquisition   $ 42,300                
Common stock, par value | $ / shares   $ 0.001                
Convertible Debt [Member]                    
Business Acquisition [Line Items]                    
Stated interest rate 0.375% 0.375%           0.375% 0.375%  
Common Class A [Member]                    
Business Acquisition [Line Items]                    
Common stock, par value | $ / shares $ 0.001             $ 0.001 $ 0.001  
Conversion ratio of common stock | shares               1    
Common Class A [Member] | NuVasive Merger Agreement [Member]                    
Business Acquisition [Line Items]                    
Conversion ratio of common stock | shares   0.75           0.75